M Mugnaini

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Selective down-regulation of [(125)I]Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine
    M Mugnaini
    Biology Department, Psychiatry CEDD, GlaxoSmithKline S p A, Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
    Neuroscience 137:565-72. 2006
  2. ncbi Upregulation of [3H]methyllycaconitine binding sites following continuous infusion of nicotine, without changes of alpha7 or alpha6 subunit mRNA: an autoradiography and in situ hybridization study in rat brain
    Manolo Mugnaini
    Biology Department, Psychiatry CEDD, GlaxoSmithKline S p A, Medicines Research Centre, Verona, Italy
    Eur J Neurosci 16:1633-46. 2002
  3. ncbi Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A
    M Quartaroli
    GlaxoWellcome S p A, Medicines Research Centre, Department of Pharmacology, Verona, Italy
    J Pharmacol Exp Ther 290:158-69. 1999
  4. ncbi Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site
    R Di Fabio
    Glaxo Wellcome S p A, Medicines Research Centre, Verona, Italy
    J Med Chem 40:841-50. 1997
  5. pmc Allosteric modulation of [3H]-CGP39653 binding through the glycine site of the NMDA receptor: further studies in rat and human brain
    M Mugnaini
    GlaxoSmithKline Group, GlaxoWellcome S p A, Medicines Research Centre, Via Fleming 4, 37100 Verona, Italy
    Br J Pharmacol 132:1883-97. 2001
  6. ncbi Receptor binding characteristics of the novel NMDA receptor glycine site antagonist [3H]GV150526A in rat cerebral cortical membranes
    M Mugnaini
    Glaxo Wellcome, Medicines Research Centre, Via Fleming 4, 37135, Verona, Italy
    Eur J Pharmacol 391:233-41. 2000
  7. ncbi Dopamine responsiveness to drugs of abuse: A shell-core investigation in the nucleus accumbens of the mouse
    Alessandro Zocchi
    Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
    Synapse 50:293-302. 2003
  8. ncbi 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists
    Fabrizio Micheli
    Psychiatry Centre of Excellence, Molecular Discovery Research, and Safety Assessment, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
    J Med Chem 50:5076-89. 2007
  9. pmc The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence
    Christian A Heidbreder
    Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
    Brain Res Brain Res Rev 49:77-105. 2005
  10. ncbi The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection
    Corrado Corti
    Department of Biology, Psychiatry Centre of Excellence in Drug Discovery, GlaxoSmithKline Medicines Research Centre, 37135 Verona, Italy
    J Neurosci 27:8297-308. 2007

Detail Information

Publications10

  1. ncbi Selective down-regulation of [(125)I]Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine
    M Mugnaini
    Biology Department, Psychiatry CEDD, GlaxoSmithKline S p A, Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
    Neuroscience 137:565-72. 2006
    ....
  2. ncbi Upregulation of [3H]methyllycaconitine binding sites following continuous infusion of nicotine, without changes of alpha7 or alpha6 subunit mRNA: an autoradiography and in situ hybridization study in rat brain
    Manolo Mugnaini
    Biology Department, Psychiatry CEDD, GlaxoSmithKline S p A, Medicines Research Centre, Verona, Italy
    Eur J Neurosci 16:1633-46. 2002
    ..Finally, the present results provide the first anatomical description of the distribution of [3H]MLA binding sites in rat brain...
  3. ncbi Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A
    M Quartaroli
    GlaxoWellcome S p A, Medicines Research Centre, Department of Pharmacology, Verona, Italy
    J Pharmacol Exp Ther 290:158-69. 1999
    ..Moreover, antagonists of the NMDA glycine site receptor could represent a new analgesic class, effective in conditions not sensitive to classical opioids...
  4. ncbi Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site
    R Di Fabio
    Glaxo Wellcome S p A, Medicines Research Centre, Verona, Italy
    J Med Chem 40:841-50. 1997
    ..According to these results the terminal phenyl ring of the C-3 side chain should lie in a nonhydrophobic pocket of limited size, refining the proposed pharmacophore model of the glycine binding site associated with the NMDA receptor...
  5. pmc Allosteric modulation of [3H]-CGP39653 binding through the glycine site of the NMDA receptor: further studies in rat and human brain
    M Mugnaini
    GlaxoSmithKline Group, GlaxoWellcome S p A, Medicines Research Centre, Via Fleming 4, 37100 Verona, Italy
    Br J Pharmacol 132:1883-97. 2001
    ..Finally, this study provides the first detailed anatomical description of the regional distribution of [(3)H]-CGP39653 binding sites in human brain...
  6. ncbi Receptor binding characteristics of the novel NMDA receptor glycine site antagonist [3H]GV150526A in rat cerebral cortical membranes
    M Mugnaini
    Glaxo Wellcome, Medicines Research Centre, Via Fleming 4, 37135, Verona, Italy
    Eur J Pharmacol 391:233-41. 2000
    ..It is concluded that [3H]GV150526A can be considered a new valuable tool to further investigate the properties of the glycine site of the NMDA receptor...
  7. ncbi Dopamine responsiveness to drugs of abuse: A shell-core investigation in the nucleus accumbens of the mouse
    Alessandro Zocchi
    Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
    Synapse 50:293-302. 2003
    ..These findings suggest that a careful evaluation of the data is required when subtle changes in extracellular levels of DA are measured...
  8. ncbi 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists
    Fabrizio Micheli
    Psychiatry Centre of Excellence, Molecular Discovery Research, and Safety Assessment, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
    J Med Chem 50:5076-89. 2007
    ....
  9. pmc The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence
    Christian A Heidbreder
    Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
    Brain Res Brain Res Rev 49:77-105. 2005
    ..Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction...
  10. ncbi The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection
    Corrado Corti
    Department of Biology, Psychiatry Centre of Excellence in Drug Discovery, GlaxoSmithKline Medicines Research Centre, 37135 Verona, Italy
    J Neurosci 27:8297-308. 2007
    ..We conclude that neuroprotection by mGlu2/3 receptor agonists requires the activation of astrocytic mGlu3 receptors, whereas, unexpectedly, activation of mGlu2 receptors might be harmful to neurons exposed to toxic insults...